VIEW MORE
VIEW MORE
Latest News
Published in Nature Medicine, a VHIO-led study has unveiled a new predictive biomarker of response to anti-BRAF/EGFR combinatory therapy in…
The Coordination and Support Action “4.UNCAN.eu” had its official kick-off on September 8-9 2022 with a public event hosted by…
Research Programs
Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.
We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).
VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.
PRINCIPAL RESEARCHERS
Events
